## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CENTENE CORP Director Kenneth A Burdick Sells Shares**
- Source: TradingView | 20251206T150817 | Neutral | Relevance: 99%
- Kenneth A Burdick, a Director and 10% owner of CENTENE CORP (CNC), sold a total of 66,007 shares of Common Stock on December 3 and 4, 2025 for $2,575,601. The sales occurred at weighted average prices of $39.04 and $39.00. Following these transactions, Burdick directly owns 272,364 shares and indirectly owns 86,498 shares through Burdick Family LLC.

**2. Centene director Burdick sells $2.57 million in stock**
- Source: Investing.com | 20251206T001529 | Neutral | Relevance: 98%
-  Centene Corp (NYSE:CNC) director Kenneth A. Burdick sold 65,907 shares of common stock for approximately $2.57 million in two separate transactions on December 3 and 4, 2025. Despite this sale, Centene is considered undervalued by InvestingPro, with a strong free cash flow yield and aggressive share buybacks by management. The company also announced expansion plans for its Medicare Advantage and Prescription Drug Plans, alongside exceeding Q3 2025 earnings estimates.

**3. Sarah London: 100 Most Influential People in Healthcare 2025**
- Source: Modern Healthcare | 20251208T170810 | Bullish | Relevance: 98%
-  Sarah London, the CEO of Centene Corp., has been recognized as one of the "100 Most Influential People in Healthcare 2025" by Modern Healthcare. She is listed as #22 on this prestigious list.

**4. Centene Corporation $CNC Shares Acquired by Amundi**
- Source: MarketBeat | 20251207T081924 | Somewhat-Bullish | Relevance: 98%
-  Amundi has increased its stake in Centene Corporation (NYSE:CNC) by 6.2% during the 2nd quarter, now owning 3,384,752 shares valued at $183,724,000. Several other hedge funds also adjusted their positions in Centene, and institutional investors and hedge funds collectively own 93.63% of the stock. Analyst ratings for Centene are mixed, with a consensus "Hold" rating and an average price target of $40.00.

**5. Marshall Wace LLP Grows Stock Holdings in Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20251206T110812 | Neutral | Relevance: 65%
-  Marshall Wace LLP significantly increased its stake in Molina Healthcare, Inc. (NYSE:MOH) by 2,768.3% in Q2, bringing its total holdings to 248,740 shares valued at approximately $74.1 million. This increase makes Marshall Wace LLP own about 0.46% of the company, while institutional investors and hedge funds collectively own about 98.5% of Molina's stock. Despite missing Q2 earnings expectations, the company provided FY2025 guidance, and analysts currently hold a "Hold" rating with an average target price of $198.93.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 14.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 13.0x attractive for 46% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.6B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 13.0 |
| Current P/E | 19.0 |
| YoY Growth | 46.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.4% to -3.1% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.85x), long-term trend not supportive. RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.10% (CS: 21) | Weak |
| RSI_14 | 53.0 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.855x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $37.88
- **Stop Loss:** $35.06 (7.4% risk)
- **Target:** $40.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 177
- **Position Value:** $6,704.76
- **Portfolio %:** 6.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*